Effects of an inhaled β 2-agonist on cardiovascular function and sympathetic activity in healthy subjects

Eric M. Snyder, Eric C. Wong, William T. Foxx-Lupo, Courtney M. Wheatley, Nicholas A. Cassuto, Asad E Patanwala

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Study Objective. To determine the effect of a short-acting, inhaled β 2-adrenergic receptor agonist, albuterol sulfate, administered by nebulization, on cardiovascular function and sympathetic activity in healthy individuals. Design. Prospective, placebo-controlled, single-blind, crossover study. Setting. University research center. Subjects. Seventeen healthy subjects. Intervention. After a screening visit to rule out cardiovascular abnormalities and anemia, each subject participated in two more separate visits. At the second visit, they were administered a single dose of either nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline or placebo (3 ml of normal saline). One week later, subjects returned for their third visit and received the other treatment. Measurements and Main Results. At the two study visits, before and 30, 60, and 90 minutes after administration of albuterol or placebo, we measured plasma catecholamine levels (epinephrine and norepinephrine), cardiac output, heart rate, and systolic and diastolic blood pressure, and we calculated stroke volume, mean arterial pressure, and systemic vascular resistance (SVR). Inhaled placebo resulted in no significant change overall in any of the measured or calculated cardiovascular parameters. Compared with baseline values, albuterol administration after 30, 60, and 90 minutes, increased cardiac output (mean ± SD 4.2 ± 1.1, 4.4 ± 1.3, and 4.3 ± 1.1 L/min, respectively, vs 3.6 ± 1.0 L/min) and stroke volume (51 ± 15, 56 ±14, and 56 ± 13 ml, respectively, vs 46 ± 12 ml), did not significantly change blood pressure, and decreased SVR (1401 ± 432, 1393 ± 424, and 1384 ± 391 dynes•sec/cm 5, respectively, vs 1661 ± 453 dynes•sec/cm 5) (p<0.05 for all comparisons). Heart rate was significantly changed with both albuterol and placebo, but only at 30 minutes after treatment. Albuterol, but not placebo, also increased plasma norepinephrine levels. Conclusion. In these healthy subjects, administration of a nebulized β 2- agonist resulted in enhanced ventricular function and a decrease in SVR, suggesting peripheral vasodilation. In addition, the increase in norepinephrine level with albuterol, but not placebo, may have important implications in patients with known cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)748-756
Number of pages9
JournalPharmacotherapy
Volume31
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Albuterol
Healthy Volunteers
Placebos
Vascular Resistance
Norepinephrine
Blood Pressure
Cardiac Output
Stroke Volume
Heart Rate
Cardiovascular Abnormalities
Single-Blind Method
Adrenergic Agonists
Ventricular Function
Vasodilation
Cross-Over Studies
Epinephrine
Catecholamines
Anemia
Arterial Pressure
Cardiovascular Diseases

Keywords

  • β-adrenergic receptors
  • β-agonist
  • Albuterol
  • Cardiovascular function
  • Catecholamines

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Effects of an inhaled β 2-agonist on cardiovascular function and sympathetic activity in healthy subjects. / Snyder, Eric M.; Wong, Eric C.; Foxx-Lupo, William T.; Wheatley, Courtney M.; Cassuto, Nicholas A.; Patanwala, Asad E.

In: Pharmacotherapy, Vol. 31, No. 8, 08.2011, p. 748-756.

Research output: Contribution to journalArticle

Snyder, Eric M. ; Wong, Eric C. ; Foxx-Lupo, William T. ; Wheatley, Courtney M. ; Cassuto, Nicholas A. ; Patanwala, Asad E. / Effects of an inhaled β 2-agonist on cardiovascular function and sympathetic activity in healthy subjects. In: Pharmacotherapy. 2011 ; Vol. 31, No. 8. pp. 748-756.
@article{9d2b39e5bc2e47429f247d5c9d60f42a,
title = "Effects of an inhaled β 2-agonist on cardiovascular function and sympathetic activity in healthy subjects",
abstract = "Study Objective. To determine the effect of a short-acting, inhaled β 2-adrenergic receptor agonist, albuterol sulfate, administered by nebulization, on cardiovascular function and sympathetic activity in healthy individuals. Design. Prospective, placebo-controlled, single-blind, crossover study. Setting. University research center. Subjects. Seventeen healthy subjects. Intervention. After a screening visit to rule out cardiovascular abnormalities and anemia, each subject participated in two more separate visits. At the second visit, they were administered a single dose of either nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline or placebo (3 ml of normal saline). One week later, subjects returned for their third visit and received the other treatment. Measurements and Main Results. At the two study visits, before and 30, 60, and 90 minutes after administration of albuterol or placebo, we measured plasma catecholamine levels (epinephrine and norepinephrine), cardiac output, heart rate, and systolic and diastolic blood pressure, and we calculated stroke volume, mean arterial pressure, and systemic vascular resistance (SVR). Inhaled placebo resulted in no significant change overall in any of the measured or calculated cardiovascular parameters. Compared with baseline values, albuterol administration after 30, 60, and 90 minutes, increased cardiac output (mean ± SD 4.2 ± 1.1, 4.4 ± 1.3, and 4.3 ± 1.1 L/min, respectively, vs 3.6 ± 1.0 L/min) and stroke volume (51 ± 15, 56 ±14, and 56 ± 13 ml, respectively, vs 46 ± 12 ml), did not significantly change blood pressure, and decreased SVR (1401 ± 432, 1393 ± 424, and 1384 ± 391 dynes•sec/cm 5, respectively, vs 1661 ± 453 dynes•sec/cm 5) (p<0.05 for all comparisons). Heart rate was significantly changed with both albuterol and placebo, but only at 30 minutes after treatment. Albuterol, but not placebo, also increased plasma norepinephrine levels. Conclusion. In these healthy subjects, administration of a nebulized β 2- agonist resulted in enhanced ventricular function and a decrease in SVR, suggesting peripheral vasodilation. In addition, the increase in norepinephrine level with albuterol, but not placebo, may have important implications in patients with known cardiovascular disease.",
keywords = "β-adrenergic receptors, β-agonist, Albuterol, Cardiovascular function, Catecholamines",
author = "Snyder, {Eric M.} and Wong, {Eric C.} and Foxx-Lupo, {William T.} and Wheatley, {Courtney M.} and Cassuto, {Nicholas A.} and Patanwala, {Asad E}",
year = "2011",
month = "8",
doi = "10.1592/phco.31.8.748",
language = "English (US)",
volume = "31",
pages = "748--756",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8",

}

TY - JOUR

T1 - Effects of an inhaled β 2-agonist on cardiovascular function and sympathetic activity in healthy subjects

AU - Snyder, Eric M.

AU - Wong, Eric C.

AU - Foxx-Lupo, William T.

AU - Wheatley, Courtney M.

AU - Cassuto, Nicholas A.

AU - Patanwala, Asad E

PY - 2011/8

Y1 - 2011/8

N2 - Study Objective. To determine the effect of a short-acting, inhaled β 2-adrenergic receptor agonist, albuterol sulfate, administered by nebulization, on cardiovascular function and sympathetic activity in healthy individuals. Design. Prospective, placebo-controlled, single-blind, crossover study. Setting. University research center. Subjects. Seventeen healthy subjects. Intervention. After a screening visit to rule out cardiovascular abnormalities and anemia, each subject participated in two more separate visits. At the second visit, they were administered a single dose of either nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline or placebo (3 ml of normal saline). One week later, subjects returned for their third visit and received the other treatment. Measurements and Main Results. At the two study visits, before and 30, 60, and 90 minutes after administration of albuterol or placebo, we measured plasma catecholamine levels (epinephrine and norepinephrine), cardiac output, heart rate, and systolic and diastolic blood pressure, and we calculated stroke volume, mean arterial pressure, and systemic vascular resistance (SVR). Inhaled placebo resulted in no significant change overall in any of the measured or calculated cardiovascular parameters. Compared with baseline values, albuterol administration after 30, 60, and 90 minutes, increased cardiac output (mean ± SD 4.2 ± 1.1, 4.4 ± 1.3, and 4.3 ± 1.1 L/min, respectively, vs 3.6 ± 1.0 L/min) and stroke volume (51 ± 15, 56 ±14, and 56 ± 13 ml, respectively, vs 46 ± 12 ml), did not significantly change blood pressure, and decreased SVR (1401 ± 432, 1393 ± 424, and 1384 ± 391 dynes•sec/cm 5, respectively, vs 1661 ± 453 dynes•sec/cm 5) (p<0.05 for all comparisons). Heart rate was significantly changed with both albuterol and placebo, but only at 30 minutes after treatment. Albuterol, but not placebo, also increased plasma norepinephrine levels. Conclusion. In these healthy subjects, administration of a nebulized β 2- agonist resulted in enhanced ventricular function and a decrease in SVR, suggesting peripheral vasodilation. In addition, the increase in norepinephrine level with albuterol, but not placebo, may have important implications in patients with known cardiovascular disease.

AB - Study Objective. To determine the effect of a short-acting, inhaled β 2-adrenergic receptor agonist, albuterol sulfate, administered by nebulization, on cardiovascular function and sympathetic activity in healthy individuals. Design. Prospective, placebo-controlled, single-blind, crossover study. Setting. University research center. Subjects. Seventeen healthy subjects. Intervention. After a screening visit to rule out cardiovascular abnormalities and anemia, each subject participated in two more separate visits. At the second visit, they were administered a single dose of either nebulized albuterol sulfate 2.5 mg diluted in 3 ml of normal saline or placebo (3 ml of normal saline). One week later, subjects returned for their third visit and received the other treatment. Measurements and Main Results. At the two study visits, before and 30, 60, and 90 minutes after administration of albuterol or placebo, we measured plasma catecholamine levels (epinephrine and norepinephrine), cardiac output, heart rate, and systolic and diastolic blood pressure, and we calculated stroke volume, mean arterial pressure, and systemic vascular resistance (SVR). Inhaled placebo resulted in no significant change overall in any of the measured or calculated cardiovascular parameters. Compared with baseline values, albuterol administration after 30, 60, and 90 minutes, increased cardiac output (mean ± SD 4.2 ± 1.1, 4.4 ± 1.3, and 4.3 ± 1.1 L/min, respectively, vs 3.6 ± 1.0 L/min) and stroke volume (51 ± 15, 56 ±14, and 56 ± 13 ml, respectively, vs 46 ± 12 ml), did not significantly change blood pressure, and decreased SVR (1401 ± 432, 1393 ± 424, and 1384 ± 391 dynes•sec/cm 5, respectively, vs 1661 ± 453 dynes•sec/cm 5) (p<0.05 for all comparisons). Heart rate was significantly changed with both albuterol and placebo, but only at 30 minutes after treatment. Albuterol, but not placebo, also increased plasma norepinephrine levels. Conclusion. In these healthy subjects, administration of a nebulized β 2- agonist resulted in enhanced ventricular function and a decrease in SVR, suggesting peripheral vasodilation. In addition, the increase in norepinephrine level with albuterol, but not placebo, may have important implications in patients with known cardiovascular disease.

KW - β-adrenergic receptors

KW - β-agonist

KW - Albuterol

KW - Cardiovascular function

KW - Catecholamines

UR - http://www.scopus.com/inward/record.url?scp=79961114854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961114854&partnerID=8YFLogxK

U2 - 10.1592/phco.31.8.748

DO - 10.1592/phco.31.8.748

M3 - Article

VL - 31

SP - 748

EP - 756

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8

ER -